Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity

J Med Chem. 2017 Aug 10;60(15):6721-6732. doi: 10.1021/acs.jmedchem.7b00671. Epub 2017 Jul 25.

Abstract

Naturally derived chemical compounds are the foundation of much of our pharmacopeia, especially in antiproliferative and anti-infective drug classes. Here, we report that a naturally derived molecule called carmaphycin B is a potent inhibitor against both the asexual and sexual blood stages of malaria infection. Using a combination of in silico molecular docking and in vitro directed evolution in a well-characterized drug-sensitive yeast model, we determined that these compounds target the β5 subunit of the proteasome. These studies were validated using in vitro inhibition assays with proteasomes isolated from Plasmodium falciparum. As carmaphycin B is toxic to mammalian cells, we synthesized a series of chemical analogs that reduce host cell toxicity while maintaining blood-stage and gametocytocidal antimalarial activity and proteasome inhibition. This study describes a promising new class of antimalarial compound based on the carmaphycin B scaffold, as well as several chemical structural features that serve to enhance antimalarial specificity.

MeSH terms

  • Antimalarials / chemical synthesis
  • Antimalarials / pharmacology*
  • Artemisinins / pharmacology
  • Dipeptides / chemical synthesis
  • Dipeptides / pharmacology*
  • Drug Design
  • Enzyme Assays
  • Hep G2 Cells
  • Humans
  • Molecular Docking Simulation
  • Oligopeptides / chemical synthesis
  • Oligopeptides / pharmacology*
  • Plasmodium falciparum / drug effects*
  • Proteasome Endopeptidase Complex / metabolism
  • Proteasome Inhibitors / chemical synthesis
  • Proteasome Inhibitors / pharmacology*
  • Saccharomyces cerevisiae / drug effects

Substances

  • Antimalarials
  • Artemisinins
  • Dipeptides
  • Oligopeptides
  • Proteasome Inhibitors
  • carmaphycin B
  • artemisinin
  • PSMB11 protein, human
  • Proteasome Endopeptidase Complex